Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Chromadex Corp CDXC

Technology Scientific & Technical Instruments
Chromadex Corp. is a global bioscience company. The Company is engaged in research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. Its segments include Consumer Products, Ingredients and Analytical Reference Standards and Services. The Consumer Products segment provides finished... see more

Recent & Breaking News (NDAQ:CDXC)

ChromaDex Launches New Patented Ingredient - IMMULINA(TM) - a Powerful, Natural Ingredient That Boosts the Immune System

GlobeNewswire September 10, 2015

ChromaDex Announces Introduction of CVS Health NIAGEN(R) NR Age Defense Supplement

GlobeNewswire September 9, 2015

ChromaDex to Host Investor Call on Wednesday, August 19th at 11am EDT

GlobeNewswire August 18, 2015

ChromaDex Reports 5th Consecutive Quarter of Record Revenue as Q2 Ingredients Sales Climb 98%

GlobeNewswire August 13, 2015

Results from First Human Clinical Study Demonstrate ChromaDex's NIAGEN(R) Nicotinamide Riboside Effectively Increases the Co-enzyme NAD+ and is Safe

GlobeNewswire August 12, 2015

ChromaDex and Collaborators Report Unexpected Discovery of Novel Biomarkers of Effective NAD+ Precursor, Nicotinamide Riboside

GlobeNewswire August 12, 2015

ChromaDex to Report Second Quarter 2015 Financial Results on Thursday, August 13, 2015

GlobeNewswire August 6, 2015

Nutrition Business Journal Honors ChromaDex With Business Achievement Award for Growth

GlobeNewswire July 29, 2015

Alsa, Featuring PURENERGY(R), Provides Sustained Energy Boost and Mental Alertness Without the Jolt of the Typical Energy Drink

GlobeNewswire July 28, 2015

ChromaDex Welcomes Business & Media Executive and Academy Award Winning Producer, Rob Fried, to Its Board of Directors

GlobeNewswire July 13, 2015

ChromaDex Announces a Collaborative Human Clinical Study on NIAGEN(R) With the University of Colorado Boulder

GlobeNewswire June 18, 2015

ChromaDex Expands Patent Rights to Pterostilbene

GlobeNewswire June 4, 2015

Healthy Directions has Launched NRG AdvantageTM Featuring NIAGEN(R)-the World's First and Only Commercially Available Form of Nicotinamide Riboside (NR)

GlobeNewswire June 2, 2015

ChromaDex Announces Exclusive Worldwide License and Supply Agreement for Anthocyanin Rich Suntava(R) Purple Corn

GlobeNewswire May 21, 2015

ChromaDex to Present at the LD Micro Invitational Conference on June 2, 2015

GlobeNewswire May 20, 2015

ChromaDex to Present at the 2015 Marcum MicroCap Conference on May 28, 2015

GlobeNewswire May 18, 2015

ChromaDex Reports 1st Quarter Record Revenue as Ingredients Sales Soar 136%

GlobeNewswire May 14, 2015

ChromaDex to Host First Quarter 2015 Investor Call on Monday, May 18th at 11 am EDT

GlobeNewswire May 11, 2015

Washington University Medical School Scientists Publish Results of Pre-Clinical Study Showing Nicotinamide Riboside is Effective in Rescuing Neurons Subjected to Trauma and Disease

GlobeNewswire April 29, 2015

Published Study Shows Topical Treatment With Pterostilbene Effectively Protects Hairless Mice Against UVB Radiation-Induced Skin Damage and Carcinogenesis

GlobeNewswire April 10, 2015